CONMED Croissance future
Future contrôle des critères 1/6
CONMED devrait augmenter ses bénéfices et son chiffre d'affaires de 13.8% et de 6.7% par an respectivement. Le BPA devrait croître de de 14.4% par an. Le rendement des capitaux propres devrait être 14.9% dans 3 ans.
Informations clés
13.8%
Taux de croissance des bénéfices
14.4%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 17.2% |
| Taux de croissance des recettes | 6.7% |
| Rendement futur des capitaux propres | 14.9% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 31 Oct 2024 |
Mises à jour récentes de la croissance future
Recent updates
CONMED's (NYSE:CNMD) Earnings Are Weaker Than They Seem
Nov 07
Earnings Beat: CONMED Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 02Should You Investigate CONMED Corporation (NYSE:CNMD) At US$71.92?
Oct 01Why We're Not Concerned About CONMED Corporation's (NYSE:CNMD) Share Price
Sep 12CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
Aug 15CONMED Corporation's (NYSE:CNMD) Intrinsic Value Is Potentially 97% Above Its Share Price
Jul 17AirSeal Concerns Have Let Too Much Air Out Of Conmed's Valuation
Jun 21There Is A Reason CONMED Corporation's (NYSE:CNMD) Price Is Undemanding
Jun 01Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching
Apr 18Is CONMED (NYSE:CNMD) Using Too Much Debt?
Mar 28CONMED Corporation (NYSE:CNMD) Might Not Be As Mispriced As It Looks After Plunging 26%
Feb 15US$111: That's What Analysts Think CONMED Corporation (NYSE:CNMD) Is Worth After Its Latest Results
Feb 03Should You Investigate CONMED Corporation (NYSE:CNMD) At US$107?
Jan 08Investors Appear Satisfied With CONMED Corporation's (NYSE:CNMD) Prospects
Dec 18CONMED (NYSE:CNMD) Takes On Some Risk With Its Use Of Debt
Nov 30Conmed: Sector Derating And A New Competitive Threat Shouldn't Overshadow A Solid Core Business
Oct 28Is CONMED Corporation (NYSE:CNMD) Potentially Undervalued?
Sep 22Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?
Aug 24Conmed: Reiterate Buy Rating As Earnings Are Expected To Grow Strongly
Jul 28Should You Think About Buying CONMED Corporation (NYSE:CNMD) Now?
Jun 08These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Extensively
May 17Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)
Apr 28Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching
Mar 10Here's Why CONMED (NYSE:CNMD) Has A Meaningful Debt Burden
Feb 14CONMED Non-GAAP EPS of $0.42 misses by $0.48, revenue of $250.9M misses by $51.58M
Feb 02Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)
Jan 24ConMed: Still Fairly Priced, Turning More Constructive
Dec 09At US$83.60, Is CONMED Corporation (NYSE:CNMD) Worth Looking At Closely?
Nov 18Conmed withdraws FY22 guidance on software implementation-related disruption
Nov 15CONMED (NYSE:CNMD) Has A Pretty Healthy Balance Sheet
Oct 11Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 1,499 | 169 | 190 | 186 | 7 |
| 12/31/2025 | 1,399 | 139 | 179 | 158 | 8 |
| 12/31/2024 | 1,302 | 118 | 137 | 129 | 8 |
| 9/30/2024 | 1,288 | 132 | 166 | 180 | N/A |
| 6/30/2024 | 1,276 | 99 | 159 | 175 | N/A |
| 3/31/2024 | 1,262 | 82 | 142 | 158 | N/A |
| 12/31/2023 | 1,245 | 64 | 106 | 125 | N/A |
| 9/30/2023 | 1,169 | 58 | 38 | 57 | N/A |
| 6/30/2023 | 1,139 | 88 | 16 | 37 | N/A |
| 3/31/2023 | 1,099 | -94 | 7 | 29 | N/A |
| 12/31/2022 | 1,045 | -81 | 12 | 33 | N/A |
| 9/30/2022 | 1,069 | -83 | 59 | 79 | N/A |
| 6/30/2022 | 1,042 | -114 | 56 | 74 | N/A |
| 3/31/2022 | 1,020 | 68 | 74 | 90 | N/A |
| 12/31/2021 | 1,011 | 63 | 97 | 112 | N/A |
| 9/30/2021 | 989 | 62 | 83 | 98 | N/A |
| 6/30/2021 | 979 | 54 | 99 | 112 | N/A |
| 3/31/2021 | 881 | 13 | 70 | 83 | N/A |
| 12/31/2020 | 862 | 10 | 52 | 65 | N/A |
| 9/30/2020 | 874 | 0 | 69 | 85 | N/A |
| 6/30/2020 | 870 | 0 | 69 | 87 | N/A |
| 3/31/2020 | 951 | 34 | 84 | 103 | N/A |
| 12/31/2019 | 955 | 29 | 75 | 95 | N/A |
| 9/30/2019 | 933 | 29 | 60 | 79 | N/A |
| 6/30/2019 | 901 | 28 | 28 | 47 | N/A |
| 3/31/2019 | 876 | 31 | 29 | 46 | N/A |
| 12/31/2018 | 860 | 41 | 58 | 75 | N/A |
| 9/30/2018 | 840 | 72 | 55 | 71 | N/A |
| 6/30/2018 | 828 | 73 | N/A | 80 | N/A |
| 3/31/2018 | 812 | 71 | N/A | 75 | N/A |
| 12/31/2017 | 796 | 55 | N/A | 66 | N/A |
| 9/30/2017 | 778 | 15 | N/A | 58 | N/A |
| 6/30/2017 | 773 | 16 | N/A | 70 | N/A |
| 3/31/2017 | 769 | 12 | N/A | 72 | N/A |
| 12/31/2016 | 764 | 15 | N/A | 40 | N/A |
| 9/30/2016 | 750 | 16 | N/A | 36 | N/A |
| 6/30/2016 | 735 | 17 | N/A | 24 | N/A |
| 3/31/2016 | 722 | 22 | N/A | 17 | N/A |
| 12/31/2015 | 719 | 30 | N/A | 51 | N/A |
| 9/30/2015 | 723 | 34 | N/A | 64 | N/A |
| 6/30/2015 | 729 | 27 | N/A | 65 | N/A |
| 3/31/2015 | 736 | 30 | N/A | 63 | N/A |
| 12/31/2014 | 740 | 32 | N/A | 65 | N/A |
| 9/30/2014 | 747 | 31 | N/A | 67 | N/A |
| 6/30/2014 | 750 | 35 | N/A | 83 | N/A |
| 3/31/2014 | 753 | 34 | N/A | 93 | N/A |
| 12/31/2013 | 763 | 36 | N/A | 81 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CNMD ( 13.8% par an) est supérieure au taux d'épargne ( 2.6% ).
Bénéfices vs marché: Les bénéfices de CNMD ( 13.8% par an) devraient croître plus lentement que le marché US ( 15.5% par an).
Croissance élevée des bénéfices: Les bénéfices de CNMD devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de CNMD ( 6.7% par an) devrait croître plus lentement que le marché de US ( 9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de CNMD ( 6.7% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de CNMD devrait être faible dans 3 ans ( 14.9 %).